10 / 36
RELAPSE-FREE SURVIVAL
Dabrafenib + trametinib
No. at risk
Placebo
100
90
80
70
60
50
40
30
20
10
0
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
Months Since Randomization
Relapse-Free Survival, %
438 405 381 354 324 281 262 249 236 227 183 148 92
47
13
2
0
432 322 263 219 198 178 168 164 157 147 128 107 63
27
4
1
0
1-year, 88%
(95% CI, 85%-91%)
1-year, 56%
(95% CI, 51%-61%)
2-year, 67%
(95% CI, 62%-72%)
3-year, 59%
(95% CI, 55%-64%)
3-year, 40%
(95% CI, 35%-45%)
4-year, 54%
(95% CI, 49%-59%)
4-year, 38%
(95% CI, 34%-44%)
2-year, 44%
(95% CI, 40%-49%)
HR 0.49
(95% CI, 0.40-0.59)